Daewoong Strikes New Deal For Botox Rival
This article was originally published in PharmAsia News
Executive Summary
After a past deal with Evolus to sell the product in the U.S. and Europe, Daewoong is searching for other markets in Asia and Latin America for its Botox competitor, and has just linked up with Turkey's Seltek.
You may also be interested in...
With Jeuveau Approval, Evolus Will Focus On The Beauty Business To Gain Market Share
Evolus believes its focus on the beauty business will be a differentiator for its neurotoxin Jeuveau. The company will publish head-to-head results against Botox alongside the Spring 2019 launch and does not expect a new trade secrets complaint from Botox maker Allergan to delay its product.
Allergan Aesthetic Medicines Head Moatazedi Moves To Emerging Competitor Evolus
David Moatazedi is leaving behind the aesthetic medicines group at Allergan to run the newly public, aesthetics-only firm Evolus, where US and EU approval of the Botox competitor DWP-450 (prabotulinumtoxinA) is imminent and the new CEO says the opportunity is unparalleled.
Allergan Relying On 'Six Stars' And Other R&D Programs To Blunt Restasis Blow
Allergan will spend 2018 trying to shift investor focus from the loss of Restasis patent exclusivity in the second half of the year to the company's R&D pipeline, including the late-stage "six stars" highlighted in 2017 and mid-stage programs that are moving into the spotlight.